Last reviewed · How we verify

Leukoreduced blood components

University of Washington · FDA-approved active Biologic ✓ Verified Jun 2026 Quality 5/100

Leukoreduced blood components is a Biologic drug developed by University of Washington. It is currently FDA-approved.

Leukoreduced blood components are used to treat conditions such as iron deficiency, transfusion-related complications, and liver transplant, as well as to study the in-vivo performance of blood component transfusion. Leukoreduced blood components are collected using systems like the Trima Accel, which uses non-DEHP disposable sets, and are stored for up to 42 days.

At a glance

Generic nameLeukoreduced blood components
SponsorUniversity of Washington
ModalityBiologic
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Leukoreduced blood components

What is Leukoreduced blood components?

Leukoreduced blood components is a Biologic drug developed by University of Washington.

Who makes Leukoreduced blood components?

Leukoreduced blood components is developed and marketed by University of Washington (see full University of Washington pipeline at /company/university-of-washington).

What development phase is Leukoreduced blood components in?

Leukoreduced blood components is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing